A fresh perspective on anticoagulant therapy in patients with cancer in the era of NOAC
open access
Abstract
Cancer is a condition associated with hypercoagulability requiring anticoagulant therapy. In recent years, oncological patients have been given heparin and vitamin K antagonists. Nowadays, non-vitamin K antagonist oral anticoagulants (NOAC) are becoming increasingly widely used. Based on the current state of knowledge, NOAC drugs can be used in anticoagulant treatment of cancer patients with caution, i.e. after assessing the bleeding risk and a risk-benefit analysis of anticoagulant therapy, as well as of the drug interactions between oncological drugs and the NOAC group.
Abstract
Cancer is a condition associated with hypercoagulability requiring anticoagulant therapy. In recent years, oncological patients have been given heparin and vitamin K antagonists. Nowadays, non-vitamin K antagonist oral anticoagulants (NOAC) are becoming increasingly widely used. Based on the current state of knowledge, NOAC drugs can be used in anticoagulant treatment of cancer patients with caution, i.e. after assessing the bleeding risk and a risk-benefit analysis of anticoagulant therapy, as well as of the drug interactions between oncological drugs and the NOAC group.
Keywords
cancer, anticoagulant treatment, non-vitamin K antagonist oral anticoagulants
About this articleTitle
A fresh perspective on anticoagulant therapy in patients with cancer in the era of NOAC
Journal
Issue
Pages
27-33
Bibliographic record
Folia Cardiologica 2020;15(1):27-33.
Keywords
cancer
anticoagulant treatment
non-vitamin K antagonist oral anticoagulants
Authors
Agnieszka Bureta
Bartosz Kwiatkowski
Małgorzata Lelonek